Paragraph 10 F1
A liquid formulation—
(a)
containing cannabidiol obtained by extraction and purification from cannabis;
(b)
where the concentration of—
(i)
delta-9-tetrahydrocannabinol is not more than 0.1 milligram per millilitre; and
(ii)
cannabidiol is 95-105 milligrams per millilitre;
(c)
which is presented in a bottle, as an oral solution for oral administration; and
(d)
which was approved for marketing by the European Commission on 19th September 2019.
Annotations
Textual amendments
- F1
Sch. 5 para. 10 inserted (24.6.2020) by The Misuse of Drugs (Amendment) (England, Wales and Scotland) Regulations 2020 (S.I. 2020/559), regs. 1(1), 2(4)
Notes on Schedule 5
Textual amendments
- F1
Words in Sch. 5 heading inserted (8.11.2023) by The Misuse of Drugs (England and Wales and Scotland) (Amendment) Regulations 2023 (S.I. 2023/1099), regs. 1(1), 8(a)